Lyn Cobley Joins Mesoblast Board, Bringing Over 30 Years Of Global Financial Services Experience

Mesoblast Limited, a global leader in allogeneic cellular therapies for inflammatory conditions, has announced the appointment of Lyn Cobley to its Board of Directors. Cobley has over 30 years of high-level experience in the financial services sector, including roles such as CEO of Westpac Institutional Bank and Group Treasurer of the Commonwealth Bank of Australia. She has also held senior positions at Barclays Capital and Citibank.

Commenting on her appointment, Ms Cobley said, “Following the recent United States Food and Drug Administration (FDA) approval of Ryoncil®, Mesoblast has become a wonderful success story for not only the Australian biotechnology industry but also the global leader in the allogeneic cell therapy industry. The Company has many exciting milestones in the near term, including the ramp-up of commercialisation and additional indications for some highly prevalent diseases. I look forward to contributing to Mesoblast's ongoing development and success in the coming years.”

Mesoblast Chair Jane Bell welcomed Ms Cobley to the Board “We are delighted to have Lyn join Mesoblast as an Independent Non-Executive Director. She has extensive corporate finance and governance experience at some of the largest institutions globally and brings a strong background in strategy and leadership, working in highly regulated industries.”

Cobley serves on the Board of the Commonwealth Bank of Australia and is involved in several advisory and leadership roles, including with Chief Executive Women, the Macquarie University Council, and EXL’s APAC Advisory Council.